Allotex
David Muller is the current President & CEO of Allotex since 2013. Prior to that, David held the same position at Avedro, Inc. from 2008 to 2015. David holds a PhD in Physical Chemistry from Cornell University and an MBA from The Wharton School.
This person is not in any teams
Allotex
Allotex Inc. is an ophthalmic biologics and device company developing new therapeutic solutions for the treatment of presbyopia, hyperopia, and myopia. The therapy is accomplished through tissue addition technology that uses precisely-shaped human corneal allografts to create what is essentially a permanent, living contact lens or lens insert.